Skip to main content
Caplight Logo









Laigo Bio

Laigo Bio

Private
UtrechtHealthcare & Life Scienceshttps://www.laigobio.com/en/

Last Round

Seed

Mar 23, 2026

Total Funding Raised

$31.5M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Laigo Bio is a biotechnology company that develops bispecific antibody-based therapeutics for oncology and immunology using its proprietary SureTAC™ precision membrane protein degradation platform.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

SureTACtargeted protein degradationTPDprotein degradermembrane protein targetingbispecific antibodiesundruggable targetsdrug discovery platformE3 ligaseoncology therapeuticsSurface Removal Targeting Chimerasimmunology therapeuticsautoimmune disease therapyneuroinflammation

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Laigo Bio Comparables

Compare Laigo Bio with similar companies based on industry and business-model similarity.

Laigo Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
GlycoEra
82%
Avilar Therapeutics
81%
Johnson & Johnson
80%

Laigo Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedMar 23, 2026
SeedDec 4, 2025
SeedFeb 8, 2022

Laigo Bio Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 1, 2026

    Grew 22% QoQ, from 18 to 22 employees.

  • Jun 23, 2026

    Grew 33% QoQ from 15 to 20 employees.

Laigo Bio Filings

Explore SEC and related filing metadata, where available.

Laigo Bio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Laigo Bio's valuation, stock price, and market status.

Is Laigo Bio a public or private company?

Laigo Bio is a private company.

What is the current stock price of Laigo Bio?

Laigo Bio is a private company with no public stock price. No recent secondary market data is available.

How much is Laigo Bio worth (valuation)?

Valuation information for Laigo Bio is not publicly available.

Can I buy Laigo Bio stock?

Laigo Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Laigo Bio's last funding round?

Laigo Bio's most recent funding round was Seed on March 23, 2026.

Who are the main investors in Laigo Bio?

Key investors in Laigo Bio include Biovance Capital Partners, Kurma Partners, Curie Capital.

Will Laigo Bio IPO soon?

No public IPO plans have been announced for Laigo Bio.

How can I track Laigo Bio secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Laigo Bio's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersUtrecht
Employee Range19
Year Founded2022
Last FundingMar 23, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?